Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anshenbunao Capsule (安神补脑胶囊) is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Nantong Jidesheng, a subsidiary of Jinghua Pharmaceutical Group. It is primarily indicated for the treatment of neurasthenia, insomnia, dizziness, and fatigue associated with kidney deficiency and insufficiency of qi and blood. The capsule typically contains a combination of herbal extracts, including *Cervus nippon* (deer antler), *Polygonum multiflorum* (fleeceflower root), *Epimedium*, *Zingiber officinale* (ginger), *Zizyphus jujuba* (jujube), and *Glycyrrhiza* (licorice), often supplemented with Vitamin B1 (thiamine). Its therapeutic approach focuses on "calming the spirit" (Anshen) and "tonifying the brain" (Bunao) to restore cognitive function and improve sleep quality.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Anshenbunao Capsule.